DIGITAL-ENVOY
14.7.2020 13:02:08 CEST | Business Wire | Press release
Digital Envoy, the inventor of IP intelligence, today announced that Jerrod Stoller has been appointed as its new President. Current President and CEO Bill Calpin has stepped back from his role and has been named Chairman of the Board. Co-founder and Executive Vice President Rob Friedman assumes a dual role with the addition of the Vice-Chairman title.
Stoller will assume day-to-day leadership of Digital Envoy, overseeing operations for all three business units: Digital Element , Digital Resolve and Gathr Lab . His focus will be driving product innovation and market strategy across all three business units to align all offerings even closer with the needs of current customers and the marketplaces at large.
“The Digital Envoy team has accomplished great things since our start in 1999, and I am extremely proud of the growth and success our teams have achieved during that time,” said Calpin. “Our accomplishments have always been reliant on the entire team and the common goal of making Digital Envoy bigger and better. As Jerrod joins the team, all of us will continue to play key roles in helping our company maximise its potential. Based on his past experiences and successes, it’s easy to understand the enthusiasm our entire team has for Jerrod joining and leading our company into the future.”
Before joining Digital Envoy, Stoller was CEO of eVestment where he had directed the sales, marketing, client success and business development activities of the organisation globally for almost 10 years. He took on the CEO role 18 months ago, while retaining his other duties. Before joining eVestment, Stoller was the Regional Manager of RSA, the Security Division of EMC, where he directed company performance into triple-digit growth. Prior to RSA, he held leadership roles with Datalex Transportation Enterprise Software, Siemens Business Services, TransQuest Business Consulting and NCR. Stoller holds a bachelor’s degree in finance from Purdue University.
“I am thrilled to assume this new role and incredibly excited about what we can accomplish together for the future,” said Stoller. “There is tremendous opportunity ahead for Digital Envoy. I look forward to continuing to support our clients at the highest levels as well as innovating new market and product strategies within our industry niches to solve real-world problems.”
All changes are effective immediately.
“As Digital Envoy has continued to grow, we felt the need to expand the team to help focus on both the operational and strategic needs of the company,” said Friedman. “For Bill and I, our new roles provide opportunities to continue to stay engaged in the business while also providing us more time to address some of the longer-term opportunities and partnerships available to us as the markets continue to change.”
About Digital Envoy
Launched in 1999, Digital Envoy introduced the concept of privacy-sensitive IP-based geolocation and IP intelligence, allowing businesses—from ad networks to publishers to websites to retailers and more—to harness the power of location and new intelligence about connected users for a multitude of mission-critical applications. Taking more of a background role, in 2005 Digital Envoy introduced two divisions to help best address the unique needs of its diverse audience segments and business applications: Digital Element, which was created to continue the legacy of providing global geolocation data and services that bring anytime, anywhere relevance and context to online and mobile initiatives; and Digital Resolve, which was launched to deliver solutions that proactively secure online accounts, information, transactions and interactions from login to logout. In 2019, Digital Envoy launched Gathr Lab to further expand on its two decades of location data expertise and provide anonymous, custom audience insights and segments at scale, across all devices. By helping clients to reach, understand and amplify their best audiences, Gathr Lab is leading change by committing to data anonymity and refreshing transparency rooted in location-based data science. Visit www.digitalenvoy.com for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200714005066/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom